汉米制药公司对BH3120的先进试验,这是一项新的癌症免疫疗法,在早期试验中很有希望。 Hanmi Pharmaceutical advances trials for BH3120, a new cancer immunotherapy showing promise in early tests.

汉米制药公司与北京汉米制药公司一起,正在推进BH3120临床试验,这是一项创新的癌症免疫疗法。 Hanmi Pharmaceutical, along with Beijing Hanmi Pharmaceutical, is advancing clinical trials for BH3120, an innovative cancer immunotherapy. 药物针对的是癌症细胞的PD-L1和免疫细胞的4-1BB,目的是提高免疫系统抗肿瘤的能力。 The drug targets PD-L1 on cancer cells and 4-1BB on immune cells, aiming to boost the immune system's ability to fight tumors. 早期试验显示没有严重的副作用,目前正在南韩进行,美国汉米公司也正在结合MSD KEYTRUDA测试BH3120,以治疗先进的固态肿瘤。 Early trials show no severe side effects and are ongoing in South Korea and the U.S. Hanmi is also testing BH3120 in combination with MSD's KEYTRUDA for treating advanced solid tumors.